Implementation of the Rules of Good Practice in Transfusion Activity at the Level of the Blood Transfusion Unit of SCJU Constanta

Introduction. Blood is a vital resource, and its use is growing worldwide. Although the demand for blood is high, there are cases in which blood products are rejected. The number of rejected blood components in hospitals is reported to be between 0.1% and 6.7%. (1–5)

Objectives. Quality management includes good practices in transfusion activity, an important part of which is limiting the rejection of labile blood products. The objective of this study is to analyze the use and rejection of blood products in the Constanza County Emergency Clinical Hospital between 2012–2021, including 2 years of the Covid-19 pandemic.

Material and method. The work presents a retrospective study of transfusion activity over a period of 10 years, with the analysis of units of labile blood products rejected compared to the number of units transfused to hospitalized patients.

Results and discussions. In our institution, with a large number of transfused patients and a very large volume of administered blood products, the rejection was on average 1.82% (3,887 rejected products out of the 213,869 received products). Most rejected products were erythrocyte concentrates (1491 units). The good practice measures implemented have led to a decrease of the number of rejected products, with a reduction of the number of rejected units in the last 3 years by an average of 142 units per year.

Conclusions. Quality assurance is a legal obligation in the transfusion sector. The implementation of the norms of good practice according to the Order M.S. no.329 / 2018 led to the decrease of the number of rejected products from 2.81% in 2018 to 1.16% in 2021. An increasingly restrictive blood test is used.